The study is a multi-center, multi-national, open label, single arm Phase II study of
single-agent cabozantinib. The objective of the study is to assess the safety and activity of
cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and
sunitinib and have not been exposed yet to other KIT- or PDGFR-directed tyrosine kinase
inhibitors.
Patient will receive cabozantinib until they experience no further benefit from the
treatment, becoming intolerant to the drug or wishing to discontinue the treatment. Treatment
beyond RECIST 1.1 progression is allowed in patients deriving clinical benefit upon
investigator's discretion, provided no other criteria for treatment withdrawal are met.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC